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Sudden cardiac death: prevention
and treatment
Sudden cardiac death remains a major health issue in western countries as
well as in Hong Kong. Despite increasing knowledge of the mechanisms and
risk factors of sudden cardiac death, methods for identifying high-risk
candidates and predicting the efficacy of measures to prevent sudden cardiac
death are still inadequate. A significant proportion of patients have known
heart disease but are generally considered to be at low risk for this event.
More efforts are needed to improve the success rate of out-of-hospital
resuscitation through better warning systems, the use of amiodarone for
refractory arrhythmias, and the widespread availability of automated
defibrillation devices to allow early defibrillation. It is likely that these
measures could increase the number of survivors following cardiac arrest.
In survivors of sudden cardiac death episodes, treatment of the underlying
cardiac disease, especially early revascularisation for myocardial ischaemia,
is required. In the majority of patients, implantation of an implantable
cardioverter defibrillator, with or without the use of an anti-arrhythmic
drug such as amiodarone, would then be used to maintain survival.
Furthermore, for individuals at significant risk of sudden cardiac death,
primary prevention of sudden cardiac death through the placement of an
implantable cardioverter defibrillator is increasingly being used.
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Introduction
Sudden death can be defined as either: (1) an unexpected natural death within a
short time period, generally 1 hour or less from the onset of symptoms; or (2) a
non-witnessed death discovered within 24 hours in someone without prior
symptoms, or any prior condition that would appear fatal. Such a rapid death
is often attributed to a cardiac cause, but it is now well recognised that classifi-
cation based on clinical circumstances is often not possible, and can be misleading,
as up to 40% of sudden deaths are non-witnessed ones. Prodromal symptoms
are often non-specific, and those taken to indicate ischaemia (chest pain), tachy-
arrhythmia (palpitations), or congestive heart failure symptoms (dyspnoea),
should only be seen as suggesting the diagnosis. Sudden cardiac death can be
prevented if high-risk patients are identified and referred to a cardiologist.
Recently, implantable cardioverter defibrillators (ICD) have been shown to be
effective in preventing sudden cardiac death in 99% of cases. Furthermore,
automated external defibrillators (AED) have been increasingly accessible
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to non-medical personnel, significantly improving survival
rates in patients at immediate risk of sudden cardiac death.
Epidemiology
In the United States, sudden cardiac death episodes affect
250 000 to 350 000 people every year, with an average
survival rate of only 5%. Cardiovascular disease accounts
for up to 89% of cases of sudden death in western popu-
lations, as shown in Table 1.1 Sudden cardiac death is
often the first manifestation of coronary heart disease, and
is responsible for approximately 50% of the mortality from
cardiovascular disease in the United States and other
developed countries. In less-developed countries, the rates
of sudden cardiac death are parallel to the rates of ischaemic
heart disease as a whole, and therefore are lower. According
to a 1997 survey in Hong Kong, the incidence of sudden
cardiac deaths was 1.8 per 100 000 population. Even when
adjusted for the population incidence of coronary artery
disease, the incidence of sudden cardiac death is still
significantly lower than the western figure. The reason for
this difference remains unclear.2
Risk factors
As the majority of individuals who suffer sudden cardiac
death have coronary heart disease, the epidemiology of
sudden cardiac death parallels that of coronary heart disease
to a large extent. Anatomic findings at autopsy include acute
changes in coronary plaque morphology, such as thrombus,
plaque disruption, or both, in more than 50% of cases of
sudden coronary death. However, up to 50% of patients at
immediate risk of sudden cardiac death due to coronary
artery disease have no manifestations of their disease prior
to that acute episode. Risk factors for sudden cardiac death
are similar to those for coronary artery disease, and include
age, hypertension, elevated serum cholesterol levels, glucose
intolerance, and smoking.
The clinical history can assist in identification of patients
at risk of sudden cardiac death. Patients with a history of a
sudden cardiac death episode, and with haemodynamic-
ally significant ventricular tachyarrhythmias are at risk of
sudden cardiac death. A prior history of myocardial infarction
can be identified in as many as 75% patients, and raises the
1-year risk of sudden cardiac death by 5%. In patients with
a history of previous myocardial infarction, the risk of
sudden death is further increased if they present with syn-
cope, with New York Heart Association class III or IV, and
have ventricular tachycardia/fibrillation early after myocardial
infarction (3 days-2 months). For patients with heart failure
due to either ischaemic or non-ischaemic cardiomyo-
pathy, the presence of left ventricular systolic dysfunction
(ejection fraction, <30%) is a major independent predictor of
total and sudden cardiac mortality. About half of all deaths
in patients with heart failure are characterised as sudden death
due to arrhythmias, and the risk of sudden cardiac death
increases as the left ventricular ejection fraction deteriorates.
In some patients, family history of cardiac diseases or
sudden cardiac death can be important. The prevalence of
hypertrophic cardiomyopathy is about 0.2% in the general
population, and about 10% of these patients are considered to
be at high risk for sudden cardiac death. Hypertrophic cardio-
myopathy is the most common cause of sudden cardiac
death in athletes younger than 35 years. Idiopathic long QT
syndrome is a congenital disorder that may lead to unexplained
syncope, seizures, and sudden cardiac death. Patients may
either remain asymptomatic, or be prone to potentially lethal
arrhythmias. For the purposes of risk stratification, a
young age at presentation, a family history of sudden car-
diac death, and a personal history of cardiac arrest are power-
ful markers of sudden cardiac death risk. A positive family
history is present in 60% of patients with long QT syndrome.
Brugada syndrome was first described in 1991, and has
since been recognised as another important cause of sudden
cardiac death in patients without structural heart disease. It
can be identified by a typical electrocardiographic (ECG)
pattern—coved-type, or less commonly, saddleback-
type ST segment elevation in precordial leads V1, and V2.
There may be associated T wave inversion and right
bundle branch block. Sudden cardiac death in patients
with Brugada syndrome is caused by fast, polymorphic
ventricular tachycardia. Sodium channel blockers, such as
procainamide, can unmask these ECG patterns in those
with apparently normal baseline ECG findings. In some
patients, this syndrome has been shown to be genetically
determined, with an autosomal dominant transmission,
linking to mutations in the cardiac sodium channel gene
SCN5A in chromosome 5, the same gene that causes long
QT syndrome. It has long been recognised that some South-
East Asian countries, such as Thailand, have a high inci-
dence of sudden death in males (26-38 per 100 000 people
per year), known as sudden unexpected death syndrome.3 It
was recently discovered that this syndrome and Brugada
syndrome share a defect in a similar gene, indicating that
they are allelic diseases, if not the same disease. In Hong
Kong, Brugada syndrome is not uncommon, and a case series
of 40 patients has been reported.4 However, the precise
genetic defects causing Brugada syndrome in Hong Kong
patients remain unclear. Certain ECG abnormalities can
help to identify patients at increased risk for sudden cardiac
death. These include the presence of atrioventricular block
or intraventricular conduction defects and QT prolongation,
an increase in resting heart rate to higher than 90 beats per
minute, and the presence of complex ventricular arrhythmias,
such as non-sustained ventricular tachycardia.
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Table 1. Underlying causes of sudden cardiac death1
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Mechanisms
A number of arrhythmias have been identified as being the
underlying mechanism leading to sudden cardiac death
(Fig 1)—ventricular tachycardia (62% of cases), bradycardia
(17%), primary ventricular fibrillation (8%), and torsades
de pointes (13%).1 In the majority of cases, sudden cardiac
death is thus due to a life-threatening ventricular tachy-
arrhythmia that develops in individuals with underlying
anatomic and functional substrates and is precipitated by
transient events (Table 2). The interplay between anatomic
and functional substrates and transient events leads to
disruption of the normal state of balance. The impact of all
three on the underlying potential arrhythmia mechanisms
intrinsic to all hearts precipitates sudden cardiac death.
Understanding this is critical to understanding the patho-
physiology of sudden cardiac death. Cardiac arrest due to
severe bradycardia, asystole, or pulseless electrical activity
(electromechanical dissociation), appears to be more
common in severely diseased hearts, probably represent-
ing more global myocardial dysfunction. The outlook for
patients exhibiting these disturbances at the time of
attempted resuscitation is poorer than for patients who
exhibit ventricular fibrillation.
Management
Treatment of patients at immediate risk of sudden
cardiac death
Treatment and prognosis depends on the type of underlying
cardiac rhythm. Furthermore, different electrophysiological
mechanisms are present in different types of cardiac disease.
The management of patients includes:
(1) initial emergency care to stabilise haemodynamic
status;
(2) investigation of the underlying causes and precipi-
tating factors; and
(3) prevention of recurrence.
Ventricular fibrillation is the type of arrhythmia most
responsive to defibrillation. However, ventricular fibrillation
tends to rapidly deteriorate into asystole, for which de-
fibrillation is ineffective. Furthermore, the success rate of
resuscitation reduces by 8% to 10% after each minute of
arrest.5 Hence, the key for successful resuscitation in patients
at immediate risk of sudden cardiac death due to ventricular
fibrillation is early defibrillation. This has led to the
development of AEDs, which allow early defibrillation for
such patients. Preliminary data published support this
option. Studies using AEDs to achieve rapid defibril-
lation (that is, within 4 minutes of cardiac arrest) have
demonstrated improved survival in a variety of settings and
situations, including by police rescuers trained in early
defibrillation,6-8 casino security personnel trained with
AEDs,9 airport personnel and non-trained members of
the public in airports using AEDs,10-12 in-flight airline
personnel,13-15 and from a broad community-based de-
fibrillation programme that included lay rescuers, police,
and public AEDs.16 Collectively, the effectiveness of early
defibrillation is well established, resulting in survival rates
approaching 50%. However, the actual impact of AED in
reducing mortality remains unclear. As up to 80% of sudden
cardiac deaths occur at home, many would not appear to be
prevented by placement of AEDs in public places. Therefore,
the cost-effectiveness of AED in the community is still
subject to further evaluation.
Until recently, no anti-arrhythmic agents administered
during cardiopulmonary resuscitation (CPR) have been
shown to be effective in shock-refractory ventricular
fibrillation. Amiodarone was recently shown to improve
Table 2. Anatomic/functional and transient factors that modulate potential arrhythmogenic mechanisms associated with
sudden cardiac death
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Fig 1. An example of a rhythm strip from Holter monitoring
during an episode of potential sudden cardiac death due to
ventricular fibrillation
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survival to hospital admission during CPR, in patients with
out-of-hospital cardiac arrest due to shock-refractory ven-
tricular fibrillation or pulseless ventricular tachycardia.17,18
Recent guidelines have recommended the use of amiodarone
as an alternative to lidocaine in shock-refractory ventricular
fibrillation or pulseless ventricular tachycardia forms of
cardiac arrest.
All patients resuscitated following sudden cardiac arrest
should be stabilised and closely monitored in an intensive
care setting, where continuous cardiac monitoring and
defibrillation equipment are available. In general,
prophylactic anti-arrhythmic therapy is not required, unless
the patient develops persistent or recurrent arrhythmia.
Disorders of electrolytes (particularly potassium, calcium,
and magnesium) should be checked and corrected. Serial
surface ECG and cardiac enzyme measurements are
required, to exclude an acute myocardial infarction. The QT
interval should be noted. Transthoracic echocardiography
is useful in assessing ventricular function and structural heart
disease. Transoesophageal echocardiography should be
reserved for cases where a transthoracic approach is
inadequate. As coronary artery disease is an important cause
of sudden cardiac arrest, coronary angiography is indicated
in the majority of patients who survive. Significant coronary
disease should be treated by revascularisation before an
electrophysiology study is performed. Aggressive therapy,
using thrombolysis in acute ischaemic syndromes, or intra-
coronary interventions resulting in reduction of myocardial
damage and scar formation and the prevention of ventricular
remodelling will diminish the occurrence of some of the
mechanisms that play a role in a fatal arrhythmia. Coronary
revascularisation is protective against ventricular arrhythmia
of ischaemic origin. An electrophysiology study is helpful
in the diagnosis of a number of important arrhythmias,
including sinus and atrioventricular nodal dysfunction,
conduction abnormalities, accessory pathways, and
inducibility of ventricular tachycardia.
Pharmacological treatment
After comprehensive evaluation and the management of
underlying causes, structural heart disease, found in the
majority of cases, must be addressed. Of the different
drugs that have been evaluated, only β-blockers and amio-
darone have been shown to reduce sudden death in those
surviving myocardial infarction. Other classes of anti-
arrhythmic agents either failed to reduce or increased the
incidence of sudden cardiac death after a myocardial
infarction. A meta-analysis from 13 trials of 6500 patients
treated with amiodarone after myocardial infarction or with
heart failure, showed a reduction in all-cause mortality,
death from arrhythmia, and sudden death.19 In patients with
diminished left ventricular function and/or ventricular ar-
rhythmias, β-blockade reduced all-cause mortality by 25%.20
Prevention of coronary artery disease through the use of
statins and aspirin are probably useful in also preventing
sudden cardiac death. The role of angiotensin-converting
enzyme inhibitors, angiotensin II blockers, and spirono-
lactone in the prevention of sudden cardiac death is more
controversial.
Implantable cardioverter defibrillators: indications
and contra-indications
An ICD is currently the most effective therapy for primary
and secondary prevention of sudden cardiac death, in
patients with ventricular tachyarrhythmia as the underlying
cause. An ICD is a small device, implanted at the pectoral
site via transvenous access. The implantation procedure can
be performed under local anaesthesia, with conscious sed-
ation. In general, it requires only a short hospital stay and
carries a low complication rate. Perioperative mortality is
below 1%. A modern ICD can provide a number of therapy
options, including bradycardia sensing, bradycardia
pacing, anti-tachycardia pacing, cardioversion, and
defibrillation.
Indications
Current indications for an ICD are summarised in Fig 2.
Secondary prevention
Secondary prevention refers to prevention of sudden cardiac
arrest in those with a known history of this event. A number
of trials (AVID [The Antiarrhythmics versus Implantable
Defibrillators], CASH [Cardiac Arrest Study Hamburg],
and CIDS [Canadian Implantable Defibrillator Study])21-23
have confirmed that an ICD is superior to anti-arrhythmic
drug treatment (mainly amiodarone) in preventing sudden
cardiac arrest in patients with previous ventricular tachy-
cardia or fibrillation and coronary artery disease. The only
current indication for ICD implantation in patients with
non-ischaemic cardiomyopathy, is secondary prevention
after an episode of resuscitated sudden death, or the presence
of ventricular tachycardia-induced syncope. The decision-
making process for secondary prevention of sudden cardiac
death in Brugada or long QT syndromes and for hyper-
trophic cardiomyopathy is very simple—an ICD is indicated.
Research to date indicates that an ICD should be the
initial treatment of choice for patients resuscitated from
documented ventricular fibrillation that is not related to a
reversible or transient cause, such as an acute myocardial
infarction. It should also be the initial treatment of choice
for patients with haemodynamically poorly tolerated
ventricular tachycardia, and probably also for patients with
a history of unexplained syncope in the presence of im-
paired ventricular function, in whom sustained ventricular
arrhythmia can be induced during electrophysiological
testing.24
Primary prevention
Primary prevention of sudden cardiac arrest is indicated in
patients without a history of sudden cardiac arrest but who
are at high risk of the event. Recent clinical trials (MADIT
[Multicenter Automatic Defibrillator Implantation Trial] I
and II, MUSTT [Multicenter Unsustained Tachycardia
Trial]) have demonstrated that use of an ICD is associated
with a 30% to 54% risk reduction for sudden cardiac arrest
in patients with prior myocardial infarction, and a low left
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ventricular ejection fraction (<30%), with or without an
inducible ventricular tachyarrhythmia during electrophysio-
logical study.25-27  The indications for an ICD as prophylactic
therapy for sudden cardiac death in patients with non-
ischaemic dilated cardiomyopathy are still uncertain. The
identification of high-risk patients with Brugada or long QT
syndrome and hypertrophic cardiomyopathy is more proble-
matic, as screening tests used in other organic heart disease
for potentially lethal ventricular arrhythmia (electrophy-
siology study, signal-averaged ECG, heart rate variability, con-
tinuous ambulatory ECG monitoring, and T-wave alternans)
have poor predictive values. For patients with hypertrophic
cardiomyopathy, the presence of two or more of the following
risk factors should prompt the decision for ICD placement:
(1) family history of sudden death;
(2) unexplained syncope;
(3) younger than 40 years;
(4) presence of an abnormal blood response during
exercise;
(5) severe and diffuse left ventricular hypertrophy; and
(6) a positive electrophysiology study, with an inducible
ventricular tachyarrhythmia demonstrated.
A more difficult decision with respect to patients with
ECG manifestation of Brugada or long QT syndrome in the
absence of symptomatic arrhythmia, and/or a family
history of sudden cardiac death has to be made. Although
the threshold for ICD implantation for primary preven-
tion is decreasing, there is no widely accepted single or
uniform approach to these syndromes. An individual
approach, with participation in the final decision by a well-
informed patient and family, is indicated in high-risk
patients with Brugada or long QT syndrome and hyper-
trophic cardiomyopathy.
* EPS electrophysiological study
† LVEF left ventricular ejection fraction
‡ SCD sudden cardiac death
§ VT/VF ventricular tachycardia/fibrillation
|| NSVT non-sustained ventricular tachycardia
Fig 2. Current indications for implantable cardioverter defibrillator use in different patient populations
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Contra-indications
An ICD is contra-indicated in the following patients:
(1) patients with syncope of undetermined aetiology,
and without a documented or inducible sustained
ventricular tachycardia;
(2) patients whose arrhythmias are due to a transient or
reversible disorder, such as acute myocardial infarction,
or electrolyte abnormalities;
(3) patients with incessant ventricular tachyarrhythmia;
(4) patients with specific arrhythmias that have a definitive
cure with catheter or surgical ablation, eg verapamil-
sensitive ventricular tachycardia, and Wolff-Parkinson-
White syndrome, and
(5) patients with a projected life expectancy of less
than 6 to 12 months, including patients with drug-
refractory heart failure, who are not candidates
for cardiac transplantation.
Conclusion
Sudden cardiac death is a common and serious medical
problem. While effective treatment is available, it is costly
and can only be applied to a small percentage of those at
risk. Currently, non-invasive methods that allow early and
accurate identification of individuals who are at risk of
sudden cardiac death are still lacking. Existing methods—
including ambulatory ECG monitoring, heart rate
variability, signal-averaged ECG, QT dispersion, and
T wave alternans—have poor positive predictive value for
identifying patients at risk of sudden cardiac death.
Although AED has proven effective in saving lives, its
cost-effectiveness in the community is still unclear.
Therefore, other alternative approaches to preventing
sudden cardiac death should focus on measures to reduce
the burden of coronary artery disease. Public education to
increase the awareness of sudden cardiac death, to promote
learning of CPR, and to develop an effective community
resuscitation service will hopefully also act to reduce the
incidence of sudden cardiac death.
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